A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL
A phase 1/2 trial of Loncastuximab tesirine in diffuse large b-cell lymphoma, run by Tanabe Pharma Corporation, active and no longer recruiting.
Overview
A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL is a phase 1/2 interventional study registered as NCT05658562 by Tanabe Pharma Corporation, with 46 participants enrolled, started 2023-01-30 and due to reach its primary completion in 2028-08. Interventions recorded: MT-2111. Conditions listed: Diffuse Large B-Cell Lymphoma. No results are recorded here; the registry entry is the source.
Setting
A Phase I/II Open-Label Study of MT-2111 in Patients With Relapsed/Refractory DLBCL
Phase
Phase 1/2
Sponsor
Tanabe Pharma Corporation
Registry
Enrolled
46
Similar pages
not linked directly; found by shared links- TrialLOTIS-2
Shares Loncastuximab tesirine, Diffuse large B-cell lymphoma.
- CompanyADC Therapeutics
Shares Loncastuximab tesirine, Diffuse large B-cell lymphoma.
- TrialStudy to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lym
Shares Loncastuximab tesirine, Diffuse large B-cell lymphoma.